Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GANX NYSE:JATT NASDAQ:LONA NASDAQ:MDCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGANXGain Therapeutics$1.68-0.6%$1.84$1.41▼$4.34$72.08M0.16713,001 shs482,863 shsJATTJATT Acquisition$10.32-1.5%$9.54$9.99▼$11.31$82.82MN/A8,240 shs166 shsLONAAthira Pharma$8.35-1.6%$9.52$2.85▼$14.21$79.75M1.9732,450 shs15,563 shsMDCXMedicus Pharma$0.34+1.5%$0.34$0.25▼$3.69$18.86M0.142.30 million shs946,514 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGANXGain Therapeutics+3.05%-9.14%-6.11%-30.45%-5.59%JATTJATT Acquisition+2.49%+0.20%-2.42%+50.07%+719.53%LONAAthira Pharma+0.71%-1.39%-16.52%+10.84%+848,999,900.00%MDCXMedicus Pharma+4.00%-10.92%+5.62%-39.00%-87.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGANXGain Therapeutics$1.68-0.6%$1.84$1.41▼$4.34$72.08M0.16713,001 shs482,863 shsJATTJATT Acquisition$10.32-1.5%$9.54$9.99▼$11.31$82.82MN/A8,240 shs166 shsLONAAthira Pharma$8.35-1.6%$9.52$2.85▼$14.21$79.75M1.9732,450 shs15,563 shsMDCXMedicus Pharma$0.34+1.5%$0.34$0.25▼$3.69$18.86M0.142.30 million shs946,514 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGANXGain Therapeutics+3.05%-9.14%-6.11%-30.45%-5.59%JATTJATT Acquisition+2.49%+0.20%-2.42%+50.07%+719.53%LONAAthira Pharma+0.71%-1.39%-16.52%+10.84%+848,999,900.00%MDCXMedicus Pharma+4.00%-10.92%+5.62%-39.00%-87.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGANXGain Therapeutics 2.67Moderate Buy$8.50405.95% UpsideJATTJATT Acquisition 0.00N/AN/AN/ALONAAthira Pharma 2.40Hold$15.0079.64% UpsideMDCXMedicus Pharma 2.25Hold$9.002,565.09% UpsideCurrent Analyst Ratings BreakdownLatest MDCX, JATT, LONA, and GANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026GANXGain Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/27/2026GANXGain Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/27/2026LONAAthira Pharma Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.005/12/2026GANXGain Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/11/2026LONAAthira Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026MDCXMedicus Pharma Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/20/2026MDCXMedicus Pharma D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.004/10/2026GANXGain Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026MDCXMedicus Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/19/2026MDCXMedicus Pharma D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGANXGain Therapeutics$50K1,433.04N/AN/A$0.48 per share3.50JATTJATT AcquisitionN/AN/A$0.38 per share27.08($0.53) per shareN/ALONAAthira PharmaN/AN/AN/AN/A$2.98 per shareN/AMDCXMedicus PharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGANXGain Therapeutics-$20.16M-$0.58N/AN/AN/AN/A-201.44%-136.24%8/11/2026 (Estimated)JATTJATT Acquisition$6.85MN/AN/AN/AN/AN/A-49.58%2.84%N/ALONAAthira Pharma-$105.61M-$5.21N/AN/AN/AN/A-381.01%-225.74%N/AMDCXMedicus Pharma-$35.46M-$2.68N/AN/AN/AN/A-3,137.84%-311.33%8/10/2026 (Estimated)Latest MDCX, JATT, LONA, and GANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026MDCXMedicus Pharma-$0.18-$0.31-$0.13-$0.31N/AN/A5/11/2026Q1 2026GANXGain Therapeutics-$0.13-$0.13N/A-$0.13$0.03 millionN/A5/7/2026Q1 2026LONAAthira PharmaN/A-$1.73N/A-$1.73N/AN/A3/26/2026Q4 2025GANXGain Therapeutics-$0.14-$0.11+$0.03-$0.11$0.03 millionN/A3/26/2026Q4 2025LONAAthira PharmaN/A-$18.90N/A-$18.90N/AN/A3/26/2026Q4 2025MDCXMedicus Pharma-$0.32-$0.82-$0.50-$0.83N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGANXGain TherapeuticsN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/ALONAAthira PharmaN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGANXGain Therapeutics0.024.694.69JATTJATT AcquisitionN/A0.150.15LONAAthira PharmaN/A10.3810.38MDCXMedicus PharmaN/A1.221.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGANXGain Therapeutics11.97%JATTJATT Acquisition47.97%LONAAthira Pharma57.12%MDCXMedicus PharmaN/AInsider OwnershipCompanyInsider OwnershipGANXGain Therapeutics4.15%JATTJATT Acquisition20.00%LONAAthira Pharma25.73%MDCXMedicus Pharma8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGANXGain Therapeutics2042.65 million40.88 millionOptionableJATTJATT Acquisition38.03 million13.80 millionNot OptionableLONAAthira Pharma409.39 million6.98 millionN/AMDCXMedicus PharmaN/A56.66 million52.07 millionN/AMDCX, JATT, LONA, and GANX HeadlinesRecent News About These CompaniesMedicus Pharma Ltd: Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix in Endometriosis utilizing the Emirati Genome ProgramJune 11 at 6:30 PM | finanznachrichten.deMedicus Pharma files IND for genomics-enabled endometriosis trial in UAEJune 11 at 8:53 AM | proactiveinvestors.comMedicus Pharma Ltd. Submits IND Application for Innovative PRECISION-E2 Phase 2a Clinical Trial in EndometriosisJune 11 at 7:51 AM | quiverquant.comQMedicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome ProgramJune 11 at 7:30 AM | globenewswire.comMedicus Pharma Ltd: Medicus Pharma Advances Teverelix Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European ...June 8, 2026 | finanznachrichten.deMedicus Pharma submits EU clinical trial modification for prostate cancer drug TeverelixJune 8, 2026 | proactiveinvestors.comMedicus Pharma submits EU clinical trial modification for prostate cancer drug TeverelixJune 8, 2026 | proactiveinvestors.comMedicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European SubmissionJune 8, 2026 | globenewswire.comMedicus Pharma advances SkinJect toward registrational trial for rare Gorlin SyndromeJune 6, 2026 | finance.yahoo.comMedicus Pharma advances SkinJect for Gorlin syndrome – ICYMIJune 6, 2026 | proactiveinvestors.comMedicus Pharma advances SkinJect for Gorlin syndrome – ICYMIJune 6, 2026 | proactiveinvestors.comMedicus Pharma Shareholders Approve Auditor, Board and ConsolidationJune 4, 2026 | tipranks.comFTSE 100 Live: Stocks heading lower despite oil falling on Israel dealJune 4, 2026 | proactiveinvestors.comMedicus Pharma advances SkinJect program with FDA submission targeting Gorlin SyndromeJune 3, 2026 | proactiveinvestors.comMedicus Pharma Advances SkinJect® into Registrational Development for Gorlin SyndromeJune 3, 2026 | globenewswire.comMedicus Pharma Ltd: Medicus Pharma Announces $22 Million Non-Dilutive FinancingMay 28, 2026 | finanznachrichten.deMedicus Pharma secures up to $22M in non-dilutive financing facilityMay 28, 2026 | proactiveinvestors.comMedicus Pharma Announces $22 Million Non-Dilutive FinancingMay 28, 2026 | globenewswire.comMedicus Pharma Secures Financing Amid Nasdaq Compliance PressureMay 27, 2026 | tipranks.comMedicus Pharma Ltd. (MDCXW) Reports FDA Progress and Expands 2026 Clinical OutlookMay 19, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDCX, JATT, LONA, and GANX Company DescriptionsGain Therapeutics NASDAQ:GANX$1.68 -0.01 (-0.59%) Closing price 04:00 PM EasternExtended Trading$1.72 +0.04 (+2.32%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.JATT Acquisition NYSE:JATT$10.32 -0.16 (-1.53%) As of 02:08 PM Eastern This is a fair market value price provided by Massive. Learn more.JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Athira Pharma NASDAQ:LONA$8.35 -0.14 (-1.65%) Closing price 04:00 PM EasternExtended Trading$8.44 +0.09 (+1.02%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.Medicus Pharma NASDAQ:MDCX$0.34 +0.00 (+1.47%) Closing price 04:00 PM EasternExtended Trading$0.34 0.00 (-0.50%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
